Atlas Trials

Immune Neoadjuvant Therapy Study of Durvalumab in Early Stage Non-small Cell Lung Cancer

Clinical trial NCT03030131 · TERMINATED

Trial details

NCT number
NCT03030131
Sponsor
Intergroupe Francophone de Cancerologie Thoracique
Status
TERMINATED
Phase
Phase 2
Study type
INTERVENTIONAL
Carcinoma, Non-Small-Cell Lung
Start date
2017-01-12
Primary completion
2019-08-28
Enrollment
50

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.